Ac immune reports full year 2024 financial results and provides a corporate update

Ac immune reports full year 2024 financial results and provides a corporate update landmark exclusive option and license deal with takeda for aci-24.060 with $100 million upfront and additional potential milestones of up to about $2.1 billion plus royalties on sales upon commercialization aci-24.060 abate phase 1b/2 trial showed encouraging interim safety and tolerability data in down syndrome (ds) cohort; further interim results in alzheimer's disease (ad) and ds expected in 2025 enrollment progress in jnj-2056 (aci-35.030) retain phase 2b trial in preclinical ad patients triggered second milestone payment of chf 24.6 million; jnj-2056 granted u.s. fda fast track designation in ad aci-7104.056 vacsyn phase 2 trial demonstrated positive interim safety and immunogenicity results in parkinson's disease (pd); further interim results in h1 2025 cash resources of chf 165.5 million at year end provides funding into q1 2027, assuming no other milestones lausanne, switzerland, march 13, 2025 – ac immune sa (nasdaq: aciu), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today reported results for the full year ended december 31, 2024, and provided a corporate update. dr. andrea pfeifer, ceo of ac immune sa, commented: “we significantly advanced our leading position in the precision prevention of neurodegenerative diseases in 2024 through strong pipeline progress and the closing of a landmark deal with takeda.
ACIU Ratings Summary
ACIU Quant Ranking